Abstract:Rationale & objective: Acute kidney injury (AKI) is a heterogeneous clinical syndrome with varying causes, pathophysiology, and outcomes. We incorporated plasma and urine biomarker measurements to identify AKI subgroups (subphenotypes) more tightly linked to underlying pathophysiology and long-term clinical outcomes. Study design: Multicenter cohort study. Setting & participants: 769 hospitalized adults with AKI matched with 769 without AKI, enrolled from December 2009 to February 2015 in the ASSESS-AKI Study. Predictors: 29 clinical, plasma, and urinary biomarker parameters used to identify AKI subphenotypes. Outcome: Composite of major adverse kidney events (MAKE) with a median follow-up period of 4.7 years. Analytical approach: Latent class analysis (LCA) and k-means clustering were applied to 29 clinical, plasma, and urinary biomarker parameters. Associations between AKI subphenotypes and MAKE were analyzed using Kaplan-Meier curves and Cox proportional hazard models. Results: Among 769 AKI patients both LCA and k-means identified 2 distinct AKI subphenotypes (classes 1 and 2). The long-term risk for MAKE was higher with class 2 (adjusted HR, 1.41 [95% CI, 1.08-1.84]; P=0.01) compared with class 1, adjusting for demographics, hospital level factors, and KDIGO stage of AKI. The higher risk of MAKE among class 2 was explained by a higher risk of long-term chronic kidney disease progression and dialysis. The top variables that were different between classes 1 and 2 included plasma and urinary biomarkers of inflammation and epithelial cell injury; serum creatinine ranked 20th out of the 29 variables for differentiating classes. Limitations: A replication cohort with simultaneously collected blood and urine sampling in hospitalized adults with AKI and long-term outcomes was unavailable. Conclusions: We identify 2 molecularly distinct AKI subphenotypes with differing risk of long-term outcomes, independent of the current criteria to risk stratify AKI. Future identification of AKI subphenotypes may facilitate linking therapies to underlying pathophysiology to prevent long-term sequalae after AKI. Plain-language summary: Acute kidney injury (AKI) occurs commonly in hospitalized patients and is associated with high morbidity and mortality. The AKI definition lumps many different types of AKI together, but subgroups of AKI may be more tightly linked to the underlying biology and clinical outcomes. We used 29 different clinical, blood, and urinary biomarkers and applied 2 different statistical algorithms to identify AKI subtypes and their association with long-term outcomes. Both clustering algorithms identified 2 AKI subtypes with different risk of chronic kidney disease, independent of the serum creatinine concentrations (the current gold standard to determine severity of AKI). Identification of AKI subtypes may facilitate linking therapies to underlying biology to prevent long-term consequences after AKI.

PHENOTYPING REPAIR AFTER ACUTE KIDNEY INJURY: PRECISION MEDICINE TO CLINICAL TRIALS

Recent Advances in Engineered Nanomaterials for Acute Kidney Injury Theranostics

Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical prospects.

Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury

Current concepts and advances in biomarkers of acute kidney injury

The Road to Precision Medicine for Acute Kidney Injury

Improving acute kidney injury diagnostic precision using biomarkers

Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm

Precision management of acute kidney injury in the intensive care unit: current state of the art

Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury

Longitudinal biomarkers and kidney disease progression after acute kidney injury

Past, Current, and Future Perspectives on Transplanting Acute Kidney Injury Kidneys

Liquid Biopsies Poorly Mirror Renal Ischemia-Reperfusion Injury

Methods for phenotyping adult patients with acute kidney injury: a systematic review

Acute kidney injury: emerging pharmacotherapies in current clinical trials

Acute kidney injury subphenotyping and personalized medicine

Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes

Personalized acute kidney injury treatment

Drugs in Development for Acute Kidney Injury

The Role of Biomarkers in the Diagnosis and Management of Acute Kidney Injury

Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review